<code id='AA2F7A0D86'></code><style id='AA2F7A0D86'></style>
    • <acronym id='AA2F7A0D86'></acronym>
      <center id='AA2F7A0D86'><center id='AA2F7A0D86'><tfoot id='AA2F7A0D86'></tfoot></center><abbr id='AA2F7A0D86'><dir id='AA2F7A0D86'><tfoot id='AA2F7A0D86'></tfoot><noframes id='AA2F7A0D86'>

    • <optgroup id='AA2F7A0D86'><strike id='AA2F7A0D86'><sup id='AA2F7A0D86'></sup></strike><code id='AA2F7A0D86'></code></optgroup>
        1. <b id='AA2F7A0D86'><label id='AA2F7A0D86'><select id='AA2F7A0D86'><dt id='AA2F7A0D86'><span id='AA2F7A0D86'></span></dt></select></label></b><u id='AA2F7A0D86'></u>
          <i id='AA2F7A0D86'><strike id='AA2F7A0D86'><tt id='AA2F7A0D86'><pre id='AA2F7A0D86'></pre></tt></strike></i>

          fashion

          fashion

          author:comprehensive    Page View:857
          Mayo Clinic, in Rochester, Minnesota on
          Photo by KEREM YUCEL/AFP via Getty Images

          SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday.

          The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P. Morgan Healthcare Conference. Mayo and Cerebras did not disclose the dollar amount, but Cerebras said it was a multimillion, multi-year contract.

          advertisement

          With roughly 380 employees, Cerebras builds and sells supercomputers specifically designed for AI applications across several industries — pitting the upstart in direct competition with the market leader Nvidia Corp. Life sciences giants including GSK have used its technology for drug discovery, and it has partnered with a health network in United Arab Emirates, but this is Cerebras’ first AI contract with a U.S. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Cue Health's Covid
          Cue Health's Covid

          BusinesswireviaAPTheFoodandDrugAdministrationwarnedconsumersMondaytonotuseCueHealth’sat-homeCovid-19

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Q&A: Jennifer Adair on making gene therapy available globally

          JenniferAdairdevelopsscalable,lowcostgenetherapiesattheFredHutchinsonCancerCenterandhelpedfoundtheGl